🏥 FDA Mandates GLP-1 Labeling Over Vision Loss Risk Manufacturers of prominent GLP-1 receptor agonists must update product labeling to reflect a potential hazard of non-arteritic anterior ischemic optic neuropathy. 🔗 Read the full story on GazeWire #Health #Biotech #Fda #GazeWire
Private to this visit. Text and context are processed by AI.